Filing Flows › Health Care › Krystal Biotech (KRYS)
Krystal Biotech (KRYS) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 2, 2026 · Krystal Biotech (KRYS) Q3 2026 earnings results →
Q3 2026 Revenue up 30% year over year to $127M · 50¢ of every $1 of revenue kept as net profit · operating margin 55.9%
Krystal Biotech made $127M in Q3 2026 (+30% Y/Y). Operating margin 55.9%, net earnings $63.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 2, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $127.3M in Q3 2026, up 30% year over year and up 7% from the previous quarter.
Operating profit was $71.1M, a 55.9% margin (up 13.6 points year over year). Of the extra revenue versus Q3 2025, 101% reached operating profit, above the 42% margin then. Total costs fell 0% while revenue rose 30%. The fastest-growing cost line was Other operating costs (+77%). Net earnings were $63.1M, down 21% year over year. The effective tax rate was 21.3%.
Operating cash flow was $91.2M (up 130% year over year), 145% of net earnings. Non-cash charges added back $1.5M of depreciation and $13.9M of share-based compensation. Working capital and other items added $12.7M. Capital expenditures of $1.0M left free cash flow of $90.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 2, 2026 | $127M | +30% | 55.9% | $63.1M | $91.2M |
| Q2 2026 | 10-Q | Aug 3, 2026 | $119M | +24% | 49.0% | $54.8M | $74.8M |
| Q1 2026 | 10-Q | May 4, 2026 | $116M | +32% | 46.1% | $55.9M | $80.4M |
| Q4 2025 | 10-K | Feb 17, 2026 | $107M | +18% | 41.3% | $51.4M | $77.5M |
| Q3 2025 | 10-Q | Nov 3, 2025 | $97.8M | +17% | 42.3% | $79.4M | $39.7M |
| Q2 2025 | 10-Q | Aug 4, 2025 | $96.0M | +37% | 41.0% | $38.3M | $52.7M |
| Q1 2025 | 10-Q | May 6, 2025 | $88.2M | +95% | 41.1% | $35.7M | $31.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Krystal Biotech
We are a fully integrated, global, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (“HSV-1”), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the transgene to treat the disease. Our vectors are amenable to formulation for non-invasive or minimally invasive routes of administration at a healthcare professional’s office or in the patient’s home by a healthcare professional, caregiver, or directly by the patient themselves.
In its own words, from its 10-K, filed Feb 17, 2026.
Krystal Biotech against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +30% against the peers' median +29%. Operating margin: 55.9% against the peers' median 40.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| KRYS Krystal Biotech | Q3 2026 | $127M | +30% | 55.9% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Krystal Biotech 10-Q on SEC EDGAR · CIK 1711279 · Biological Products, (No Diagnostic Substances)
Guidance and outlook
13F: who owns KRYS and who is buying
More on KRYS
- How Krystal Biotech makes money: revenue by segment
- Krystal Biotech next earnings date and what analysts expect
- Krystal Biotech stock forecast, price target and fair value
- Who owns Krystal Biotech stock: holders, funds and Congress trades
- Krystal Biotech guidance and outlook
- Krystal Biotech recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results